Compare Abbott Laboratories (ABT) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Howmet Aerospace Inc — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while Howmet Aerospace Inc trades at $281.21 (market cap $112.20B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | HWM | |
|---|---|---|
Market Cap | $187.95B | $112.20B |
Sector | Health | Industrials |
52-Week High | $136.62 | $291.28 |
52-Week Low | $82.57 | $171.00 |
Enterprise Value | $214.96B | $116.30B |
Dividend Yield | 2.32% | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Howmet Aerospace (HWM) trades at $283.80, up 0.03% today, with a bullish technical signal and strong support at $279. The company reported Q2 2026 EPS of $1.33, beating estimates, and raised full-year guidance due to robust aerospace and defense demand. Revenue grew 24% year-over-year, with a net income margin of 20.52% and ROE of 34.89%.
Outlook is positive with 84% analyst buy ratings and a $334.63 consensus price target, implying 18% upside. Risks include high valuation multiples (P/E 60.63) and capital expenditure increases. Earnings momentum and institutional confidence support further growth, but investors should monitor execution on expanded capacity plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
